Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2025 Earnings Conference Call. [Operator ...

RedChip Companies will air interviews with Aptevo Therapeutics, Inc. (NASDAQ:APVO) and 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) on the RedChip Small Stocks, Big Money™ show, a sponsored program ...

Q2 2025 Management View David J. Mazzo, President and CEO, reported that Lisata executed on several clinical and corporate milestones, including a research agreement with Catalent to explore ...

Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, Thursday, August 7, 2025. Lisata Therapeutics ...

Cardiol Therapeutics reports topline results from phase II ARCHER trial of CardiolRx in acute myocarditis patients: Toronto, Ontario Friday, August 8, 2025, 12:00 Hrs [IST] Cardio ...

Relay Therapeutics beat analyst estimates for both GAAP revenue and earnings per share in Q2 2025. The company reported continued clinical advancement of its lead asset RLY-2608, with new positive ...

It comes amid a warning that too often this phase of someone’s life “is seen as unexpected or a last-minute crisis” ...

NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque ...

Q4 2025 from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN, a severe, rare form of dementia with no ...

Reiterate top-line data readout from CBeyond™ Phase 2a study of nimacimab planned late Q3/early Q4 2025Patient enrollment in ...

Corvus Pharmaceuticals reported a net loss per share of $(0.10) for Q2 2025, a smaller loss than the analyst estimate of $(0.13). Research and development expenses rose sharply to $7.9 million, ...